Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts

European Urology

Volumn 57, Issue 3, 2010, Pages 446-452

  Tilling, Kate ^a   Garmo, Hans ^b   Metcalfe, Chris ^a   Holmberg, Lars ^b   Hamdy, Freddie C ^c   Neal, David E ^d   Adolfsson, Jan ^e   Martin, Richard M ^a   Davis, Michael ^a   Fall, Katja ^f   Lane, J Athene ^a   Adami, Hans Olaf ^e,f   Bill Axelson, Anna ^g   Johansson, Jan Eric ^h   Donovan, Jenny L ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e KAROLINSKA INSTITUTE   (Sweden)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g UPPSALA UNIVERSITY   (Sweden)

^h ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Active surveillance; Localised prostate cancer; PSA doubling time; PSA velocity; Reference ranges

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SCANDINAVIA; UNITED KINGDOM; WATCHFUL WAITING;

AGED; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 74649086644     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.03.023     Document Type: Article

References (22)

1. Lu-Yao G., Albertsen P.C., Barry M.J., et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality. BMJ 325 (2002) 740
2. Frankel S., Davey Smith G., Donovan J., and Neal D. Screening for prostate cancer. Lancet 361 (2003) 1122-1128
3. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977-1984
4. Bill-Axelson A., Holmberg L., Filén F., et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst 100 (2008) 1144-1154
5. Collin S.M., Martin R.M., Metcalfe C., et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 9 (2008) 445-452
6. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
7. Albertsen P.C., Hanley J.A., Penson D.F., Barrows G., and Fine J. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 177 (2007) 932-936
8. Donovan J.L., Hamdy F.C., Neal D.E., et al. Prostate testing for cancer and treatment (ProtecT) feasibility study. Health Technol Assess 7 (2003) 1-42
9. Klotz L., and Nam R. Active surveillance with selective delayed intervention for favourable risk prostate cancer: clinical experience and a "number needed to treat" analysis. Eur Urol Suppl 5 (2006) 479-486
10. Parker C. Active surveillance: an individualized approach to early prostate cancer. BJU Int 92 (2003) 2-3
11. Martin R.M., Gunnell D., Hamdy F., Neal D., Lane A., and Donovan J. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. J Urol 176 (2006) 439-449
12. Inoue L.Y., Etzioni R., Slate E.H., Morrell C., and Penson D.F. Combining longitudinal studies of PSA. Biostatistics 5 (2004) 483-500
13. Fall K., Garmo H., Andrén O., et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 99 (2007) 526-532
14. Bosch J.L.H.R., Tilling K., Bohnen A.M., and Donovan J.L. Establishing normal reference ranges for PSA change with age in a population-based study: the Krimpen study. Prostate 66 (2006) 335-343
15. Blanker M.H., Groeneveld F.P., Prins A., Bernsen R.M.D., Bohnen A.M., and Bosch J.L.H.R. Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: the Krimpen study of male urogenital tract problems and general health status. BJU Int 85 (2000) 665-671
16. Tilling K., Sterne J.A.C., Rudd A.G., Glass T.A., Wityk R.J., and Wolfe C.D.A. A new method for predicting recovery after stroke. Stroke 32 (2001) 2867-2873
17. Tilling K., Sterne J.A.C., and Wolfe C.D.A. Multilevel growth curve models with covariate effects: application to recovery after stroke. Stat Med 20 (2001) 685-704
18. Goldstein H. Kendall's Library of Statistics 3: Multilevel Statistical Models. 3rd ed. (2003), Hodder Arnold, London, UK
19. Stata [computer programme]. Version 9.0. College Station, TX; StataCorp; 2005.
20. Johansson J.E., Andrén O., Andersson S.O., et al. Natural history of early, localized prostate cancer. JAMA 291 (2004) 2713-2719
21. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomised Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
22. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter [published correction appears in N Engl J Med 2004;351:1470]. N Engl J Med 350 (2004) 2239-2246